Neurocrine Biosciences (NBIX) Tops Q4 EPS by 37c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.91, $0.37 better than the analyst estimate of $0.54. Revenue for the quarter came in at $247.9 million versus the consensus estimate of $260.49 million.

"In 2020, we served more patients with tardive dyskinesia than ever before despite the pandemic weighing on the development of the overall market. We are pleased with the recently updated guidelines from the American Psychiatric Association that now recommend first-line treatment for tardive dyskinesia with a VMAT2 inhibitor, which we hope will benefit even more patients as the vast majority of patients living with tardive dyskinesia remain undiagnosed," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "In 2021, we plan to initiate eight mid-to-late stage clinical studies and look forward to important data read-outs for NBI-1065844 in the negative symptoms of schizophrenia and valbenazine for the treatment of chorea associated with Huntington\'s Disease."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Trustmark Corp (TRMK) Tops Q1 EPS by 7c
• Retail Opportunity Investments (ROIC) Tops Q1 EPS by 2c, reaffirms guidance